Cargando…

Oxidative stress promotes fibrosis in systemic sclerosis through stabilization of a kinase-phosphatase complex

Systemic sclerosis (SSc) is a fibrotic autoimmune disease characterized by pathogenic activation of fibroblasts enhanced by local oxidative stress. The tyrosine phosphatase PTP4A1 was identified as a critical promoter of TGF-β signaling in SSc. Oxidative stress is known to functionally inactivate ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruiyuan, Kumar, Ganesan Senthil, Hansen, Uwe, Zoccheddu, Martina, Sacchetti, Cristiano, Holmes, Zachary J., Lee, Megan C., Beckmann, Denise, Wen, Yutao, Mikulski, Zbigniew, Yang, Shen, Santelli, Eugenio, Page, Rebecca, Boin, Francesco, Peti, Wolfgang, Bottini, Nunzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089796/
https://www.ncbi.nlm.nih.gov/pubmed/35451370
http://dx.doi.org/10.1172/jci.insight.155761
Descripción
Sumario:Systemic sclerosis (SSc) is a fibrotic autoimmune disease characterized by pathogenic activation of fibroblasts enhanced by local oxidative stress. The tyrosine phosphatase PTP4A1 was identified as a critical promoter of TGF-β signaling in SSc. Oxidative stress is known to functionally inactivate tyrosine phosphatases. Here, we assessed whether oxidation of PTP4A1 modulates its profibrotic action and found that PTP4A1 forms a complex with the kinase SRC in scleroderma fibroblasts, but surprisingly, oxidative stress enhanced rather than reduced PTP4A1’s association with SRC and its profibrotic action. Through structural assessment of the oxo-PTP4A1-SRC complex, we unraveled an unexpected mechanism whereby oxidation of a tyrosine phosphatase promotes its function through modification of its protein complex. Considering the importance of oxidative stress in the pathogenesis of SSc and fibrosis, our findings suggest routes for leveraging PTP4A1 oxidation as a potential strategy for developing antifibrotic agents.